Introduction. In the Russian Federation, against the background of the improvement of the main indicators for tuberculosis, problems remain associated with a consistently high detection of patients with drug resistance. The situation is getting worse, identifying new risks of tuberculosis treatment, uncontrolled use of antibiotics by the population in a pandemic. Aims: to characterize the profile of antibiotic resistance in patients with newly diagnosed tuberculosis in the conditions of the use of antibacterial drugs by the population as an antikovid therapy. Materials and methods. An analysis was carried out among newly identified patients with tuberculosis by molecular genetic research methods (n=1682) and bacterial research methods (n=1630) in the period from 2017 to 2020 according to drug resistance indicators. The results of the study. It was found that in the period from 2015 to 2017, the indicators of drug resistance in tuberculosis patients were almost at the same level. The leading antimicrobial drugs in demand among the population were ceftriaxone, azithromycin, levofloxacin, moxifloxacin, azithromycin. At the same time, the maximum increase in sales in 2020 relative to 2019 data up to 150% was determined among quinolone derivatives of moxifloxacin, levofloxacin, which began to be used in the treatment of coronavirus infection. At the same time, these drugs are traditionally used for the treatment of tuberculosis, but in 2020, an alarming trend was revealed limiting the treatment of tuberculosis patients. Primary resistance of mycobacteria was established in newly diagnosed tuberculosis patients, also for the same antimicrobial drugs of quinolone derivatives, and the increase in the proportion of patients with primary drug resistance to levofloxacin, moxifloxacin in 2020 compared to 2018 data ranged from 189 to 480%; whereas for other antibiotics the increase averaged up to 60.8%. Discussion. The obtained results suggest the development of a promising new scientific direction in the conditions of a full-scale experiment to establish the dynamics of changes in the primary resistance of not only tuberculosis pathogens, but also a number of other infectious diseases in the conditions of the use of antimicrobial drugs by the population in the treatment of COVID-19. Conclusion. The findings suggest an alarming scenario in which drug resistance develops towards highly virulent and highly drug-resistant genotypes.